Chronic cardiorenal syndrome
Conditions
Interventions
exposure group:Basic drug therapy combined with Qishen Yiqi Dropping Pills
non-exposed group:Basic drug therapy
Sponsors
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age 18~80 years old gender is not limited; 2) Meet the diagnostic criteria of chronic heart failure and chronic kidney disease; 3) New York Heart Association (NYHA) cardiac function class II~III; 4) Chronic kidney disease stage G2~G3 based on estimated glomerular filtration rate; 5) The patients gave informed consent and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1) concomitant combination of severe hepatic insufficiency hematological system endocrine system and other primary diseases tumor patients severe neuroendocrine system diseases and psychiatric patients; 2) combination of acute coronary syndrome (within 30 days) cardiogenic shock acute myocarditis hypertension (systolic blood pressure = 180mmHg and/or diastolic blood pressure = 110mmHg) difficult to control with medication difficult to control the malignant Arrhythmia hypertrophic obstructive cardiomyopathy severe valvular disease requiring surgical treatment and pulmonary embolism and other high risk factors for death; (3) Patients with chronic heart failure who recently required device therapy; (4) Pregnant or preparing for pregnancy and lactation; (5) Allergic individuals or individuals with a known allergy to the therapeutic drug; (6) Participants in a clinical study of another drug within 1 month; (7) Patients who in the judgment of the investigator are unable to complete this study or (vii) Patients who in the judgment of the investigator are unable to complete the study or to comply with the follow-up of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-minute walk test; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood urea nitrogen;Trimethylamine N-oxide;Serum creatinine;Veterans Specific Activity Questionnaire;NYHA Cardiac Function Classification;C-reactive protein;Kansas City Cardiomyopathy Questionnaire;Major renal and cardiovascular adverse events;N-terminal pro-brain natriuretic peptide/ brain natriuretic peptide;Glomerular Filtration Rate; | — |
Countries
China
Contacts
Public ContactXuezheng Liu
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed